Mirum Pharmaceuticals, Inc. (MIRM) Income Statement

The steady sequential revenue increase from $77.9M to $185.7M indicates the product franchise is still expanding in absolute terms, but the decline in year-over-year growth rates from triple digits to the high 30s percent suggests the early launch-phase tailwind is fading. Investors should monitor whether the growth rate stabilizes in the 30 to 40 percent range, which would support a durable commercial trajectory, or continues to compress toward low-teens levels that would warrant a reassessment of the revenue ramp thesis.

The expansion from the mid-70s to above 80 percent gross margin, combined with stable COGS as a share of revenue, suggests the product carries meaningful pricing power and favorable manufacturing scale. Because gross profit has grown in step with revenue, the margin profile appears structurally sound, though the reported figures alone cannot confirm whether this level is sustainable under payer pricing pressure.

Operating expenses of roughly $196M in the latest quarter, dominated by R&D of $107.9M and SG&A of $88.9M, consume more than the full $150.5M gross profit, so operating leverage has not yet emerged. The trend from a -39.5% margin in 2026Q1 to -32.2% in 2026Q3 shows some improvement, but the pace suggests a substantial revenue increase or expense discipline would be required before operating income turns positive.